Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Legend Biotech (LEGN) EBITDA (2019 - 2025)

Historic EBITDA for Legend Biotech (LEGN) over the last 7 years, with Q3 2025 value amounting to $40.6 million.

  • Legend Biotech's EBITDA fell 3603.49% to $40.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $137.7 billion, marking a year-over-year increase of 20084.14%. This contributed to the annual value of -$146.9 billion for FY2024, which is 5643.92% down from last year.
  • According to the latest figures from Q3 2025, Legend Biotech's EBITDA is $40.6 million, which was down 3603.49% from $1.2 million recorded in Q2 2025.
  • Over the past 5 years, Legend Biotech's EBITDA peaked at $137.6 billion during Q4 2024, and registered a low of -$206.1 million during Q2 2023.
  • Moreover, its 5-year median value for EBITDA was -$38.8 million (2022), whereas its average is $9.6 billion.
  • Per our database at Business Quant, Legend Biotech's EBITDA tumbled by 25407.7% in 2021 and then soared by 4181157.14% in 2023.
  • Quarter analysis of 5 years shows Legend Biotech's EBITDA stood at $89.8 million in 2021, then grew by 21.62% to $109.2 million in 2022, then surged by 41811.57% to $45.8 billion in 2023, then skyrocketed by 200.51% to $137.6 billion in 2024, then tumbled by 99.97% to $40.6 million in 2025.
  • Its EBITDA stands at $40.6 million for Q3 2025, versus $1.2 million for Q2 2025 and $60.7 million for Q1 2025.